Update: Four trials ongoing; growing discovery momentum
e-Therapeutics’ solid cash position supports increased investment in both development and discovery activities. Four clinical trials are ongoing: three with lead oncology asset ETS2101. ETS2101 data, expected by year-end, should formalise indication selection for the key Phase Ib/II trials planned for 2015, results of which could catalyse a licensing deal. Pipeline growth is also expected as investment in computational capabilities has increased the rate of compound testing in discovery. Three projects are currently being pursued, with plans for near-term evaluation of another seven. The first project(s) should enter preclinical trials by early 2016.E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.